RE:RE:RE:RE:Is anyone one adding? Why or why not? Will likely vote my 600k shares against most board members at this point. I am not under any illusions that, even collectively, we will likely have little to no impact; however, I do feel as though we gave management and the board a pass last year with the hope th we would hear our very real concerns and make measurable, tangible change.
I now find myself in a situation where I feel as though we've been placated in the wake of our grumbling last year with little to no change in management's capital market strategy and overall IR effort. They've essentially leaned heavily on their science, which while promising, has also seen significant delays from target deadlines, leaving us all wondering what is actually happening at the company with respect to their pipeline all while watching them consistently miss analyst revenues for their legacy business with one disappointment after the next. Obviously the latest PR at face value is relatively insignificant - 2% of revenue likely offset by reduced expenses certainly doesn't warrant the sell-off we've seen since, but it highlights an underlying mistrust in management and sows doubt in everyone's mind as to what we don't know about their other endeavors.
At some point, the bleeding has to stop and they need to know that the way they operate needs to change if they want to continue the good work they're doing with any kind of support from their investors.